181 related articles for article (PubMed ID: 12947394)
1. RAF antisense oligonucleotide as a tumor radiosensitizer.
Kasid U; Dritschilo A
Oncogene; 2003 Sep; 22(37):5876-84. PubMed ID: 12947394
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profile by inhibiting Raf-1 protein kinase in breast cancer cells.
Mewani RR; Tian S; Li B; Danner MT; Carr TD; Lee S; Rahman A; Kasid UN; Jung M; Dritschilo A; Gokhale PC
Int J Mol Med; 2006 Mar; 17(3):457-63. PubMed ID: 16465392
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Raf-1 protein kinase by antisense phosphorothioate oligodeoxyribonucleotide is associated with sensitization of human laryngeal squamous carcinoma cells to gamma radiation.
Soldatenkov VA; Dritschilo A; Wang FH; Olah Z; Anderson WB; Kasid U
Cancer J Sci Am; 1997; 3(1):13-20. PubMed ID: 9072302
[TBL] [Abstract][Full Text] [Related]
4. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
Mewani RR; Tang W; Rahman A; Dritschilo A; Ahmad I; Kasid UN; Gokhale PC
Int J Oncol; 2004 May; 24(5):1181-8. PubMed ID: 15067340
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome.
Gokhale PC; Zhang C; Newsome JT; Pei J; Ahmad I; Rahman A; Dritschilo A; Kasid UN
Clin Cancer Res; 2002 Nov; 8(11):3611-21. PubMed ID: 12429653
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies.
Dritschilo A; Huang CH; Rudin CM; Marshall J; Collins B; Dul JL; Zhang C; Kumar D; Gokhale PC; Ahmad A; Ahmad I; Sherman JW; Kasid UN
Clin Cancer Res; 2006 Feb; 12(4):1251-9. PubMed ID: 16489081
[TBL] [Abstract][Full Text] [Related]
8. Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells.
McPhillips F; Mullen P; MacLeod KG; Sewell JM; Monia BP; Cameron DA; Smyth JF; Langdon SP
Carcinogenesis; 2006 Apr; 27(4):729-39. PubMed ID: 16332724
[TBL] [Abstract][Full Text] [Related]
9. VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo.
Normand N; Valamanesh F; Savoldelli M; Mascarelli F; BenEzra D; Courtois Y; Behar-Cohen F
Mol Vis; 2005 Mar; 11():184-91. PubMed ID: 15761390
[TBL] [Abstract][Full Text] [Related]
10. Raf: a strategic target for therapeutic development against cancer.
Beeram M; Patnaik A; Rowinsky EK
J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185
[TBL] [Abstract][Full Text] [Related]
11. Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.
Pastorino F; Brignole C; Marimpietri D; Di Paolo D; Zancolli M; Pagnan G; Ponzoni M
Ann N Y Acad Sci; 2004 Dec; 1028():90-103. PubMed ID: 15650235
[TBL] [Abstract][Full Text] [Related]
12. Antisense raf oligodeoxyribonucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implication for gene therapy of radioresistant cancer.
Gokhale PC; Soldatenkov V; Wang FH; Rahman A; Dritschilo A; Kasid U
Gene Ther; 1997 Dec; 4(12):1289-99. PubMed ID: 9472552
[TBL] [Abstract][Full Text] [Related]
13. Antisense oligonucleotide therapy in urology.
Kausch I; Böhle A
J Urol; 2002 Jul; 168(1):239-47. PubMed ID: 12050550
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis.
Khatib AM; Fallavollita L; Wancewicz EV; Monia BP; Brodt P
Cancer Res; 2002 Oct; 62(19):5393-8. PubMed ID: 12359742
[TBL] [Abstract][Full Text] [Related]
15. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
16. First- and second-generation antisense inhibitors targeted to human c-raf kinase: in vitro and in vivo studies.
Monia BP
Anticancer Drug Des; 1997 Jul; 12(5):327-39. PubMed ID: 9236850
[No Abstract] [Full Text] [Related]
17. Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells.
Pirollo KF; Hao Z; Rait A; Ho CW; Chang EH
Biochem Biophys Res Commun; 1997 Jan; 230(1):196-201. PubMed ID: 9020045
[TBL] [Abstract][Full Text] [Related]
18. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
[TBL] [Abstract][Full Text] [Related]
19. CpG immunomer DNA enhances antisense protein kinase A RIalpha inhibition of multidrug-resistant colon carcinoma growth in nude mice: molecular basis for combinatorial therapy.
Nesterova MV; Johnson NR; Stewart T; Abrams S; Cho-Chung YS
Clin Cancer Res; 2005 Aug; 11(16):5950-5. PubMed ID: 16115938
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3.
Li WC; Ye SL; Sun RX; Liu YK; Tang ZY; Kim Y; Karras JG; Zhang H
Clin Cancer Res; 2006 Dec; 12(23):7140-8. PubMed ID: 17145839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]